Primary liver cancer
Conditions
Interventions
Treatment group:Stereotactic radiotherapy combined with sindilizumab and bevacizumab
Sponsors
Eastern Hepatobiliary Surgery Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Men or non-pregnant women aged between 18 and 70; 2. Sign informed consent; 3. The investigator believed that the patients were capable of complying with the study protocol; 4. Hepatocellular carcinoma (HCC) was diagnosed histologically or cytologically or clinically. Patients with cirrhosis were diagnosed clinically using AASLD criteria, while patients without cirrhosis were diagnosed histologically. 5. Imaging examination confirmed the presence of portal vein cancer thrombus; 6. The disease is not suitable for radical surgery; 7. Has not received any antitumor therapy in the past; 8. At least 1 measurable (measurable according to RECIST1.1) untreated lesion.
Exclusion criteria
Exclusion criteria: 1) Local treatment (including radiofrequency ablation and external radiotherapy) was performed before enrollment. 2) The tumor has developed distant metastasis, such as metastasis of lung, brain, bone, etc 3) Imaging suggested the formation of hepatic vein and vena cava cancer thrombus. 4) Severe varicose esophagus and gastric fundus veins, prone to gastrointestinal bleeding, or previous history of massive gastrointestinal bleeding; 5) Patients with heart, lung and renal insufficiency. Oral administration of warfarin and other anticoagulant drugs within 2 weeks. 6) Researchers believe that participants should not participate in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions and complications;Overall survival time;disease control rate;progression-free survival time;surgical resection rate; | — |
Countries
China
Contacts
Public Contactshuqun Cheng
Eastern Hepatobiliary Surgery Hospital
Outcome results
None listed